Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Malignant mesenchymal tumor 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × brostallicin × Gynecologic × Clear all
NCT00410462 2014-08-08

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Unknown
118 enrolled
GynecologicSarcoma

Malignant mesenchymal tumor, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡